Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.73 |
| ▸ | RAF1 | P04049 | 13/20 | 0.70 |
| ▸ | CDK8 | P49336 | 3/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | MUSK | O15146 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | PDE6D | O43924 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | CDK14 | O94921 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sc-43 SCHEMBL29367145 | 0.92 | RAF1 (0.67) | KDRRAF1CDK8BRAFRET | |
| Sc-43 SCHEMBL14684295 | 0.92 | RAF1 (0.67) | KDRRAF1CDK8BRAFRET | |
| Sc-43 SCHEMBL29492117 | 0.92 | RAF1 (0.67) | KDRRAF1CDK8BRAFRET | |
| SCHEMBL15746582 | 0.90 | KDR (0.74) | KDRRAF1CDK8BRAFMEN1 | |
| SCHEMBL16628037 | 0.90 | KDR (0.59) | KDRRAF1CDK8BRAFEGFR | |
| SCHEMBL4555004 | 0.87 | KDR (0.70) | KDRMEN1EPHX2CA7KMT2A | |
| SCHEMBL13556629 | 0.85 | RAF1 (0.72) | KDRRAF1CDK8BRAFMEN1 | |
| SCHEMBL18615606 | 0.85 | RAF1 (0.59) | KDRRAF1CDK8BRAFRET | |
| SCHEMBL18615962 | 0.85 | KDR (0.67) | KDRRAF1CDK8BRAFMEN1 | |
| SCHEMBL16628078 | 0.85 | KDR (0.73) | KDRRAF1CDK8BRAFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | Ferro Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | AIFM2, GPX4, DDIT3 | KDR 4064/4885RAF1 1212/4885CDK8 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.